Market Overview

UPDATE: Stifel Nicolaus Initiates Synta Pharmaceuticals at Hold; Enthusiasm Outpaces Expectations

Related SNTA
Synta Announces Presentation of Results from an Investigator-Sponsored Phase 1 Trial of Ganetespib in HER2+ Metastatic Breast Cancer
Synta Announces FDA's Oncologic Drugs Advisory Committee to Discuss Pediatric Uses for Ganetespib

Stifel Nicolaus initiated its coverage on Synta Pharmaceuticals (NASDAQ: SNTA) with a Hold rating, as the company may be rushing development on its promising pipeline.

Stifel Nicolaus said, "While we view Ganetespib as the leading Hsp90 inhibitor in clinical development, we remain cautious on the conduct and expectations for the ongoing Phase 2b/3 GALAXY trial in NSCLC. … Lastly we believe the expectation for top-line results from the Phase 3 portion by mid 2014 is not feasible since the median survival for second-line NSCLC treated with Taxotere monotherapy is about 6-7 months. In our opinion lofty expectations that are not likely to be met, will not likely be positively perceived by investors."

Synta Pharmaceuticals closed at $6.75 on Wednesday.

Latest Ratings for SNTA

Aug 2014JMP SecuritiesMaintainsMarket Outperform
Mar 2014Stifel NicolausDowngradesHoldSell
Mar 2014BMO CapitalDowngradesMarket PerformUnderperform

View More Analyst Ratings for SNTA
View the Latest Analyst Ratings

Posted-In: Stifel NicolausAnalyst Color Initiation Intraday Update Analyst Ratings


Related Articles (SNTA)

Around the Web, We're Loving...

Get Benzinga's Newsletters